Skip Navigation LinksHome > March 2012 - Volume 34 - Issue 2 > Preclinical Testing of Tandutinib in a Transgenic Medullobla...
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e3182309fe4
Original Articles

Preclinical Testing of Tandutinib in a Transgenic Medulloblastoma Mouse Model

Ohshima-Hosoyama, Sachiko MD, PhD*; Davare, Monika A. PhD; Prajapati, Suresh I. MSc*; Abraham, Jinu PhD; Lal, Sangeet PhD; Nelon, Laura D. BSc*; Kilcoyne, Aoife MD*,‡; Giles, Francis J. MD; Hanes, Martha A. DVM§; Rubin, Brian P. MD, PhD; Keller, Charles MD

Collapse Box

Abstract

Overexpression of platelet-derived growth factor receptor alpha (PDGFR-A) has been documented in association with primary tumors and metastasis in medulloblastoma. Tumors from our genetically engineered sonic hedgehog-driven medulloblastoma mouse model overexpress PDGFR-A in primary tumors and thus this mouse model is a good platform with which to study the role of PDGFR-A in this central nervous system malignancy. We hypothesized that inhibition of PDGFR-A in medulloblastoma can slow or inhibit tumor progression in living individuals. To test our hypothesis, we targeted PDGFR-A mediated tumor growth in vitro and in vivo using the tyrosine kinase inhibitor, tandutinib (MLN-518), which strongly inhibits PDGFR-A. Although PDGFR-A inhibition by this agent resulted in reduced mouse tumor cell growth and increased apoptosis in vitro, and reduced tumor cell proliferation in vivo, tandutinib did reduce tumor volume at the doses tested (360 mg/kg) in vivo. Thus, tandutinib may be an agent of interest for sonic hedgehog-driven medulloblastoma if a synergistic drug combination can be identified.

© 2012 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/JPHOonline

For additional oncology content, visit LWW Oncology Journals on Facebook.